Treatment of advanced pancreatic cancer using CHT102

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the safety and efficacy of CHT102, an allogeneic CAR-T cell therapy targeting mesothelin, in patients with advanced pancreatic cancer. The study consists of a dose escalation phase with three planned cohorts, followed by a dose expansion phase after a safety review. Participants will be monitored for safety, pharmacokinetics, and preliminary efficacy data throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ability to understand and sign a written informed consent documen；
2. At the date of signing ICF, 18 \~70 years old, male or female；
3. Histopathological confirmed advanced or metastatic pancreatic cancer patients who have failed to standard treatment or intolerance with standard treatment；
4. Positive mesothelin expression;
5. At least one measurable lesion at baseline per RECIST version 1.1；
6. The expected survival time is more than 12 weeks;
7. ECOG 0-1 points;
8. Adequate organ functions.

Where it's running

• Tianjin Medical University Cancer Institute & Hospital
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Jihui Hao, Ph.D
• Email: haojihui@tjmuch.com
• Phone: +86-02223340123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Celiac plexus block plus first-line systemic therapy for advanced biliopancreatic cancer with pain

  This study will try giving a celiac plexus block alongside standard first-line cancer drugs to see if it reduces pain and helps people with advanced bile duct or pancreatic cancer.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07326137

• IBI343 plus gemcitabine and albumin‑bound paclitaxel for advanced pancreatic cancer

  This trial will test whether adding IBI343 to gemcitabine and albumin‑bound paclitaxel helps people with CLDN18.2‑positive advanced pancreatic adenocarcinoma.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT06770439

• Using tumor infiltrating lymphocytes to treat advanced liver and pancreatic cancers

  This study is testing a new treatment using immune cells from tumors to see if it can help people with advanced liver and pancreatic cancers who haven't responded to regular therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai, Shanghai Municipality · NCT05098197

• Early diagnosis of pancreatic cancer using duodenal fluid biomarkers

  This project will see if pancreatic fluid collected during routine endoscopy can help detect early pancreatic cancer in adults.

  Recruiting at 3 sites Asan Medical Center · Aurora, Colorado and 2 other locations · NCT07030348

• INV-6452 in adults with HR+/HER2- advanced/metastatic breast cancer or other solid tumors

  This study tests INV-6452 to see if it is safe and tolerable and to get a first look at its activity in adults with HR+/HER2- advanced breast cancer or other advanced solid tumors.

  Recruiting Phase 1/2 Shenzhen Ionova Life Sciences Co., Ltd. · Shanghai, Shanghai Municipality · NCT07612891

• Targeted activated dendritic cell plus CAR‑T therapy for advanced solid cancers

  This trial will try combining activated dendritic cells with CAR‑T cells to see if the treatment is safe and helps adults with advanced solid tumors that express Claudin 18.2, GCC, TROP2, or PSMA.

  Recruiting Early Phase 1 Hainan Cancer Hospital · Haikou, Hainan · NCT07475182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.